benzyl 4-vinylpiperidine-1-carboxylate | 138163-09-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 4-vinylpiperidine-1-carboxylate
• 英文别名: Benzyl 4-ethenylpiperidine-1-carboxylate
• CAS: 138163-09-4
• 化学式: C₁₅H₁₉NO₂
• mdl: MFCD28110679
• 分子量: 245.321
• InChiKey: BKXGBWISORPRSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  benzyl 4-vinylpiperidine-1-carboxylate 在 zinc/copper couple 、 palladium 10% on activated carbon 、 氢气 、 sodium hydride 、 三氯氧磷 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 tert-butyl 4-(3-(2-ethoxy-2-oxoethyl)cyclobutyl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] GPR119 AGONISTS
  [FR] AGONISTES DE GPR119

  摘要：

  本公开至少部分地涉及用于治疗涉及肠脑轴的疾病或疾病的GPR119激动剂。在某些实施例中，GPR119激动剂是肠道限制化合物。在某些实施例中，该疾病或疾病是代谢性疾病，例如糖尿病，肥胖症，非酒精性脂肪性肝炎（NASH）或营养失调，例如短肠综合症。

  公开号：

  WO2022216709A1
• 作为产物：
  描述：

  N-Cbz-哌啶-4-羧酸 在 4-二甲氨基吡啶 、 cobalt(II) bromide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.08h， 生成 benzyl 4-vinylpiperidine-1-carboxylate
  参考文献：
  名称：

  钴催化氧化还原活性脂肪族酯的脱羧Negishi偶联

  摘要：

  开发了氧化还原活性脂族酯与有机锌试剂的钴催化脱羧Negishi偶联反应。该方法可以在温和的反应条件下进行高效的烷基-芳基，烷基-烯基和烷基-炔基偶联反应，而无需外部配体或添加剂。原位激活方案的成功实施和药物分子（±）-preclamol的轻松合成凸显了该方法的合成潜力。机理研究表明，涉及一种根本机制。

  DOI：

  10.1002/anie.201806799

文献信息

• [EN] N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS DE N-ARYLE ET DE N-HÉTÉROARYLE PIPÉRIDINE EN TANT QU'AGONISTES DES RÉCEPTEURS HÉPATIQUES X, COMPOSITIONS ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2018068297A1

  公开（公告）日：2018-04-19

  Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor(LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  提供的是某些取代的N-芳基和N-杂芳基哌啶化合物，其化学式为(I)以及药用可接受的盐，其中R1、R2、R3、L、R4、L1、Q、R5和R6定义如所述。所述新颖化合物，以及包含其化合物的药用可接受组合物，可能用作肝X-β受体(LXRβ)激动剂，并可用于治疗或预防与之相关的病理学。这类病理学包括但不限于炎症性疾病和以胆固醇和脂质代谢缺陷为特征的疾病，例如阿尔茨海默病。
• Biaryl piperidine amide compounds and methods of use thereof
  申请人：Athenex, Inc.

  公开号：US10450303B2

  公开（公告）日：2019-10-22

  The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.

  本申请涉及双芳基哌啶酰胺化合物或其药学上可接受的盐、溶液剂和原药及其使用方法。
• Analogues of the low-efficacy partial GABAA agonist 4-PIOL. Syntheses and in vitro pharmacological studies
  作者：M De Amici、B Frølund、H Hjeds、P Krogsgaard-Larsen

  DOI：10.1016/0223-5234(91)90198-v

  日期：1991.9

  4-PIOL (3-hydroxy-5-(4-piperidyl)isoxazole) is a low-efficacy GABA(A) agonist showing a dominating GABA(A) antagonist profile. Three dihydro analogues of 4-PIOL were synthesized, including (RS)-3-hydroxy-5-(4-piperidyl)-2-isoxazoline (1). The synthesis of 1 was based on a regioselective 1,3-dipolar cyclo-addition reaction between 1-benzyloxycarbonyl-4-vinylpiperidine (7) and bromonitrile oxide, prepared in situ from dibromoformoxime. Furthermore, the spiro analogues of 1 3-hydroxy-1-oxa-2,8-diazaspiro[4.5]dec-2-ene (2) and (RS)-3-hydroxy-1-oxa-2,7-diazaspiro[4.5]dec-2-ene (3) were were synthesized regiospecifically via cycloaddition of bromonitrile oxide to the N-benzyloxycarbonyl-protected forms of 4-methylenepiperidine (11) and 3-methylenepiperidine (15), respectively. In contrast to 4-PIOL, none of the new compounds 1-3 showed detectable effects on the binding of H-3-GABA(A) or the subunit-selective GABA(A) agonist, H-3-THIP, to GABA(A) receptor sites, and they did not significantly affect the muscimol-stimulated binding of H-3-diazepam to the benzodiazepine site of the GABA(A) receptor complex.
• BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Athenex, Inc.

  公开号：US20210347763A1

  公开（公告）日：2021-11-11

  The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
• [EN] CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS<br/>[FR] DÉRIVÉS DE CYCLOAMINO COMME ANTAGONISTES DU GPR119
  申请人：PROSIDION LTD

  公开号：WO2011147951A1

  公开（公告）日：2011-12-01

  Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.